Key findings • Sarcoidosis patients are prone to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, increased severity, morbidity and greater mortality of coronavirus disease 2019 ...

Dr. Jad Kebbe, a pulmonologist at the University of Oklahoma Health Sciences Center, discusses the risks of inhaling wildfire ...

Sarcoidosis is a systemic inflammatory disorder of unknown etiology, characterized by the formation of noncaseating granulomas, multisystem involvement, intrathoracic (pulmonary and lymph node ...

With $75.1 million in cash and minimal competition, aTyr Pharma is well-positioned financially, making it a compelling high-risk, high-reward investment. Read more on ATYR stock here.

Hiring Dalia Rayes as head of commercial for the global efzofitimod franchise slots another piece of the puzzle into place.

Topline data from Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected in the third quarter of 2025.Fourth positive DSMB ...

Xentria, a clinical-stage biopharmaceutical company advancing therapies for rare and serious diseases, today announced the successful completion of enrollment in the therapeutic dose-ranging phase of ...